Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers
Jongeneel G, Greuter M, Kunst N, van Erning F, Koopman M, Medema J, Vermeulen L, Ijzermans J, Vink G, Punt C, Coupé V. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1726-1734. PMID: 34162659, PMCID: PMC7611620, DOI: 10.1158/1055-9965.epi-21-0078.Peer-Reviewed Original ResearchConceptsConsensus molecular subtypesStage II colon cancerGuideline strategyEarly cost-effectiveness analysisColon cancer deathsPrognostic molecular markersMarkov cohort modelDutch societal perspectiveCancer treatment selectionCost-effectiveness analysisAdjuvant chemotherapyAdjuvant treatmentCancer deathCost-effectiveness assessmentMolecular subtypesTreatment selectionCurrent evidenceColon cancerSocietal perspectiveDecision uncertaintyMolecular markersCohort modelPatientsMarkersVOI analysis